Effect of Huashi Runzao Prescription on Primary Sjögren's Syndrome

WU Zihua; HUANG Ziwei; CHEN Jiaqi; HE Qian; YANG Jianying; ZHANG Yan; LIAO Jiahe; YU Xinbo; LUO Jing; TAO Qingwen

doi:10.13422/j.cnki.syfjx.20231593

您当前的位置：

首页 >

文章列表页 >

Effect of Huashi Runzao Prescription on Primary Sjögren's Syndrome

更新时间：2023-05-17

- Effect of Huashi Runzao Prescription on Primary Sjögren's Syndrome
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 29, Issue 8, Pages: 45-51(2023)
- 作者机构：
  
  1.北京中医药大学，北京 100029
  2.中日友好医院，免疫炎性疾病北京市重点实验室，北京 100029
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20231593
  CLC： R242;R2-0;R2-031;R593;R24
- Published：20 April 2023，
  
  Published Online：10 February 2023，
  
  Received：02 November 2022，
- 稿件说明：
扫描看全文
吴子华,黄子玮,陈嘉琪等.化湿润燥方治疗原发性干燥综合征的临床疗效[J].中国实验方剂学杂志,2023,29(08):45-51.

WU Zihua,HUANG Ziwei,CHEN Jiaqi,et al.Effect of Huashi Runzao Prescription on Primary Sjögren's Syndrome[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(08):45-51.
吴子华,黄子玮,陈嘉琪等.化湿润燥方治疗原发性干燥综合征的临床疗效[J].中国实验方剂学杂志,2023,29(08):45-51. DOI： 10.13422/j.cnki.syfjx.20231593.

WU Zihua,HUANG Ziwei,CHEN Jiaqi,et al.Effect of Huashi Runzao Prescription on Primary Sjögren's Syndrome[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(08):45-51. DOI： 10.13422/j.cnki.syfjx.20231593.

摘要

目的

观察化湿润燥方治疗原发性干燥综合征（pSS）燥湿互结证患者的疗效和安全性。

方法

105例符合纳入标准的pSS燥湿互结证患者，分为观察组65例和对照组40例，分别给予化湿润燥方与硫酸羟氯喹口服治疗，疗程12周。采用视觉模拟评分量表（VAS）对症状进行评估。比较两组患者治疗前后干燥、疲乏、肢体疼痛症状，欧洲风湿病联盟（EULAR）干燥综合征患者报告指数（ESSPRI），EULAR干燥综合征疾病活动度指标（ESSDAI）及免疫炎症指标变化，并观察不良反应。

结果

与本组治疗前比较，治疗后观察组患者ESSPRI评分降低（

0.01）；与对照组治疗后比较，观察组评分更低（

0.05）。与本组治疗前比较，观察组患者口干、眼干、总体干燥、疲乏、肢体疼痛VAS评分较治疗前下降（

0.01）；与对照组治疗后比较，观察组患者口干、总体干燥VAS评分更低（

0.01）。与本组治疗前比较，两组患者ESSDAI评分均下降（

0.05，

0.01），但治疗后组间比较两组患者差异无统计学意义。与本组治疗前比较，观察组患者免疫球蛋白M（IgM）下降（

0.01）、补体C3上升（

0.01），对照组患者补体C3下降（

0.05），但治疗后组间比较两组患者差异无统计学意义。治疗过程中，对照组患者出现1例胃痛，经对症治疗后缓解；观察组无不良反应发生。经卡方检验，两组患者不良反应发生率差异无统计学意义。

结论

化湿润燥方能有效改善pSS燥湿互结证患者的干燥、疲乏、肢体疼痛症状，降低疾病活动度，且安全性良好。

Abstract

Objective

To observe the efficacy and safety of Huashi Runzao prescription for patients with primary Sjögren's syndrome （pSS） of combined dryness and dampness pattern.

Method

A total of 105 eligible patients were randomized into the experimental group （65 cases） and control group （40 cases）， and they were respectively treated with Huashi Runzao prescription and hydroxychloroquine for 12 weeks. Visual Analogue Scale （VAS） was employed to assess the symptoms. The symptoms of dryness， fatigue， and pain， European League Against Rheumatism （EULAR） Sjögren's Syndrome Patient Reported Index （ESSPRI）， EULAR Sjögren's syndrome disease activity index （ESSDAI）， and immune inflammatory indicators before and after treatment were compared between the two groups， and adverse reactions were observed.

Result

After treatment， the ESSPRI score was lower than that before treatment in the experimental groups （

0.01） and was lower in the experimental group than in the control group （

0.05）. The VAS scores of dry mouth， dry eyes， overall dryness， fatigue， and pain in the experimental group decreased compared with those before treatment （

0.01）， and the experimental group had lower VAS scores of dry mouth and overall dryness than the control group （

0.01）. After treatment， the ESSDAI score of both groups decreased compared with that before treatment （

0.05，

0.01）， but there was no significant difference between the groups. After treatment， the level of immunoglobulin M （IgM） decreased （

0.01） and the level of complement C3 increased （

0.01） in the experimental group， while the level of complement C3 decreased in the control group （

0.05）. There was no significant difference in the laboratory indexes between groups. During the treatment， stomachache occurred to one case in the experimental group， which was alleviated after the treatment， and no adverse reaction was observed in the control group. According to the chi-square test， the occurrence of adverse reactions was insignificantly different between the two groups.

Conclusion

Huashi Runzao prescription can alleviate the symptoms of dryness， fatigue， and pain， and reduce disease activity without associated side effects in pSS patients with combined dampness and dryness pattern.

关键词

干燥综合征燥痹燥湿互结化湿润燥治疗化湿润燥方

Keywords

Sjögren's syndromeZaobicombined dampness and dryness patternresolving dampness and moistening drynesstreatmentHuashi Runzao prescription

references

张文，厉小梅，徐东，等.原发性干燥综合征诊疗规范［J］.中华内科杂志，2020，59（4）：269-276.

TARN J，LENDREM D，MCMEEKIN P，et al.Primary Sjögren's syndrome：Longitudinal real-world，observational data on health-related quality of life［J］.J Intern Med，2022，291（6）：849-855.

PRICE E J，RAUZ S，TAPPUNI A R，et al.The British Society for Rheumatology guideline for the management of adults with primary Sjögren's syndrome［J］.Rheumatology （Oxford），2017，56（10）：1828.

BOWMAN S J，EVERETT C C，O'DWYER J L，et al.Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjögren's syndrome［J］.Arthritis Rheumatol，2017，69（7）：1440-1450.

CARSONS S E，VIVINO F B，PARKE A，et al.Treatment guidelines for rheumatologic manifestations of Sjögren's syndrome：Use of biologic agents，management of fatigue，and inflammatory musculoskeletal pain［J］.Arthritis Care Res （Hoboken），2017，69（4）：517-527.

BRITO-ZERÓN P，RETAMOZO S，GHEITASI H，et al.Erratum to：Treating the underlying pathophysiology of primary Sjögren syndrome：Recent advances and future prospects［J］.Drugs，2016，76（18）：1799.

姜泉，张华东，陈祎，等.路志正治疗干燥综合征经验［J］.中医杂志，2016，57（6）：463-465.

许丽璇，刘建璟，徐莹银，等.中药配方口服治疗干燥综合征疗效的Meta分析［J］.湖南中医杂志，2021，37（10）：168-176.

黄淑霞，曹天雨，肖战说，等.中药联合硫酸羟氯喹治疗干燥综合征疗效和安全性的Meta分析［J］.海南医学院学报，2022，28（9）：685-693.

宋威江，罗静，申洪波，等.原发性干燥综合征中医证候分布及诊断标准研究进展［J］.中华中医药杂志，2020，35（1）：380-382.

罗静，张丽宁，陈嘉琪，等.原发性干燥综合征患者舌象特点及其与证候的相关性研究［J］.中华中医药杂志，2021，36（6）：3653-3656.

张丽宁，陈嘉琪，胡琪，等.不同舌象原发性干燥综合征患者的免疫炎症特点［J］.世界中西医结合杂志，2021，16（9）：1710-1713.

SHIBOSKI C H，SHIBOSKI S C，SEROR R，et al.2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome：A consensus and data-driven methodology involving three international patient cohorts［J］.Ann Rheum Dis，2017，76（1）：9-16.

国家中医药管理局.中医临床诊疗术语第2部分：证候：GB/T 16751.2-2021［S］.北京，2021：156-157.

SEROR R， RAVAUD P， MARIETTE X， et al. EULAR Sjogren's Syndrome Patient Reported Index （ESSPRI）： Development of a consensus patient index for primary Sjogren's syndrome［J］. Ann Rheum Dis，2011，70（6）：968-972.

SEROR R， BOWMAN S J， BRITO-ZERON P， et al.EULAR Sjogren's syndrome disease activity index （ESSDAI）： A user guide［J］.RMD Open，2015，1（1）：e000022.

TARN J，LENDREM D，MCMEEKIN P，et al.Primary Sjögren's syndrome：Longitudinal real-world，observational data on health-related quality of life［J］.J Intern Med，2022，291（6）：849-855.

HUANG T，LI Y，LUO Y，et al.Research progress on the pathogenesis and quality of life of patients with primary Sjögren's syndrome complicated by depression［J］.Clin Exp Rheumatol，2022，40（3）：647-654.

GOTTENBERG J E，RAVAUD P，PUÉCHAL X，et al.Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome：The JOQUER randomized clinical trial［J］.JAMA，2014，312（3）：249-258.

FENG Z，ZHANG B Q，ZHU Y M，et al.The Effectiveness and safety of total glucosides of paeony in primary Sjögren's syndrome：A systematic review and Meta-analysis［J］.Front Pharmacol，2019，10：550.

徐愿，罗静，韩曼，等.中医药治疗风湿免疫领域临床优势病种的探讨［J］.中国实验方剂学杂志，2022，28（9）：198-204.

罗静，徐愿，周新尧，等.中医临床优势病种探讨——干燥综合征［J］.中国实验方剂学杂志，doi：2023，10.13422/j.cnki.syfjx.20231691http://dx.doi.org/10.13422/j.cnki.syfjx.20231691

李增变，周全，张国胜，等.基于津液代谢理论观察沙参麦冬汤联合白芍总苷胶囊治疗原发性干燥综合征［J］.中国实验方剂学杂志，2020，26（20）：100-104.

程丹丹，李永明，侯佳奇，等.基于Treg细胞功能的稳定性探讨解毒通络生津方对干燥综合征模型鼠免疫调节作用［J/OL］.中国实验方剂学杂志：1-16［2022-10-31］.http：//kns.cnki.net/kcms/detail/11.3495.R.20220619.2244.005.htmlhttp://kns.cnki.net/kcms/detail/11.3495.R.20220619.2244.005.html

廖佳禾，张丽宁，张燕，等.原发性干燥综合征舌苔剥脱患者的临床特点［J/OL］.中国实验方剂学杂志：1-9［2022-11-02］.https：//doi.org/10.13422/j.cnki.syfjx.20231598https://doi.org/10.13422/j.cnki.syfjx.20231598.

张燕，杨建英，张丽宁，等.不同病程原发性干燥综合征患者的舌象与证候特点［J］.中国实验方剂学杂志，2023，doi：10.13422/j.cnki.syfjx.20231590http://dx.doi.org/10.13422/j.cnki.syfjx.20231590.

陈嘉琪，杨建英，吴子华，等.原发性干燥综合征合并间质性肺病的中医证候特点及相关因素分析［J/OL］.中国实验方剂学杂志：1-7［2022-11-02］.http：//kns.cnki.net/kcms/detail/11.3495.R.20221026.1748.004.htmlhttp://kns.cnki.net/kcms/detail/11.3495.R.20221026.1748.004.html.

SANDOVAL-FLORES M G，CHAN-CAMPOS I，HERNÁNDEZ-MOLINA G.Factors influencing the EULAR Sjögren's Syndrome Patient-Reported Index in primary Sjögren's syndrome［J］.Clin Exp Rheumatol，2021，133（6）：153-158.

COOPER C，WRATTEN S，WILLIAMS-HALL R，et al.Qualitative research with patients and physicians to assess content validity and meaningful change on ESSDAI and ESSPRI in Sjögren's［J］.Rheumatol Ther，2022，9（6）：1499-1515.

SEROR R，THEANDER E，BRUN J G，et al.Validation of EULAR primary Sjögren's syndrome disease activity （ESSDAI） and patient indexes （ESSPRI）［J］.Ann Rheum Dis，2015，74（5）：859-866.

WANG X，ZHANG T，GUO Z，et al.The efficiency of hydroxychloroquine for the treatment of primary Sjögren's syndrome：A systematic review and Meta-analysis［J］.Front Pharmacol，2021，12：693796.

KRUIZE A A，HENÉ R J，KALLENBERG C G，et al.Hydroxychloroquine treatment for primary Sjögren's syndrome：A two year double blind crossover trial［J］.Ann Rheum Dis，1993，52（5）：360-364.

BODEWES I，GOTTENBERG J E，VAN HELDEN-MEEUWSEN C G，et al.Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren's syndrome in the JOQUER randomized trial［J］.Rheumatology （Oxford），2020，59（1）：107-111.

RAMOS-CASALS M，BRITO-ZERÓN P，SOLANS R，et al.Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index：Analysis of 921 Spanish patients（GEAS-SS Registry）［J］.Rheumatology（Oxford），2014，53（2）：321-331.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Huashi Runzao Prescription on Structure and Function of Submandibular Gland in Sjögren's Syndrome Model Mice

Methodological Evaluation of Advantages of Traditional Chinese Medicine Treatment of Sjögren's Syndrome

Mechanism of Active Components of Chinese Medicine in Treatment of Idiopathic Pulmonary Fibrosis： A Review

Immunoregulatory Effect of Jiedu Tongluo Shengjin Prescription on Sjögren's Syndrome Mice Based on Stability of Treg Cells

Expert Consensus on Clinical Diseases Responding Specifically to Traditional Chinese Medicine： Sjögren's Syndrome

Related Author

HE Qian

LIAO Jiahe

CHEN Guangyao

LUO Jing

TAO Qingwen

YU Xinbo

HUANG Ziwei

WU Zihua

Related Institution

Japan Friendship Hospital

Beijing Key Lab for Immune-Mediated Inflammatory Diseases

Hospital of PLA Joint Logistics Support Force

The First Affiliated Hospital of Heilongjiang University of Chinese Medicine

Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰